What Centrexion Therapeutics does

Centrexion Therapeutics is a privately held, late clinical-stage biopharmaceutical company founded in 2013 and headquartered at One Boston Place in Boston, Massachusetts. The company is developing a diversified pipeline of novel, non-opioid clinical-stage medicines intended to treat chronic pain by targeting the underlying pathophysiology of pain with specificity to both type and source. It has subsequently expanded into immunology and inflammation, pursuing differentiated therapies for autoimmune diseases characterized by high unmet medical need. Specific drug candidates are not publicly disclosed on the company website, though the pipeline is described as multiple drug candidates at various clinical stages.

The company is led by an experienced biopharmaceutical management team, including former Pfizer Chairman and CEO Jeffrey B. Kindler as CEO, Celgene founder Sol Barer, Ph.D. as Chairman, and Johns Hopkins Professor Emeritus of Neurosurgery James N. Campbell, M.D. as President and Chief Scientific Officer. In 2025 the company transitioned its Chief Medical Officer role, with Randall Stevens, M.D. moving to Chief Medical Strategist and Charles Oh, M.D. joining as CMO. Centrexion maintains strategic co-development partnerships with Eli Lilly, Boehringer Ingelheim, NIH, and Sanofi, and has cumulatively raised approximately $229 million across 12 funding rounds from 2013 through 2020, with investors including New Enterprise Associates, InterWest Partners, 6 Dimensions Capital, ArrowMark Partners, Quan Capital, EFung Capital, Exome Asset Management, and SLR Capital Partners.

Centrexion operates with 11–50 employees and currently serves the United States only. As a clinical-stage company with no approved or commercialized products, it has no disclosed revenue; its business model relies on equity and debt capital to fund R&D, with future commercialization expected to occur via pharmaceutical partnerships and standard pharmaceutical supply chains post-regulatory approval. Pricing of pipeline therapies is not publicly disclosed.

Name

Centrexion Therapeutics

Legal name

Centrexion Therapeutics Corp.

Website

https://centrexion.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Centrexion Therapeutics is a privately held, late clinical-stage biopharmaceutical company developing novel non-opioid therapies for chronic pain and immunology medicines for autoimmune diseases, with partnerships including Eli Lilly, Boehringer Ingelheim, NIH, and Sanofi.

Ownership category

akta.pro rank

Product category

Non-opioid Pain Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Non-opioid pain therapeutics
• Clinical-stage biopharmaceuticals
• Immunology drug development
• Chronic pain treatments
• Autoimmune disease pipeline

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Core offering

Centrexion Therapeutics is a late clinical-stage biopharmaceutical company developing a diversified pipeline of novel, non-opioid medicines for the treatment of chronic pain and an expanding portfolio of immunology and inflammation therapeutics targeting autoimmune diseases. The company operates across two therapeutic areas: a pain pipeline focused on non-opioid therapies and an immunology portfolio addressing indications with high unmet medical needs. Specific drug candidate names are not publicly disclosed, and no products are yet approved or commercialized.

Product overview

Centrexion Therapeutics is a clinical-stage biopharmaceutical company developing a diversified pipeline of novel, non-opioid clinical stage medicines for the treatment of chronic pain and autoimmune diseases. The company operates across two therapeutic areas: (1) a pain pipeline focused on non-opioid therapies targeting specific types and sources of chronic pain, and (2) an expanding immunology and inflammation portfolio targeting differentiated medicines in indications with high unmet medical needs. The pipeline consists of multiple drug candidates at various clinical stages, though specific product names are not publicly disclosed on the company website. The company leverages its clinical team's track record in autoimmune drug development, including experience with blockbuster and transformative therapies, to advance its programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Non-Opioid Pain Pipeline

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Four partnerships are on record, tiered core.

• Eli Lilly and CompanycoreStrategic or Co-development PartnerEli Lilly is listed as a prestigious partner of Centrexion Therapeutics. The partnership focuses on high-value markets with significant unmet need, particularly in non-opioid pain drug development. Governmental and private support for such collaborations is growing as the industry shifts toward non-opioid pain therapeutics.
• Boehringer IngelheimcoreStrategic or Co-development PartnerBoehringer Ingelheim is listed as a prestigious partner of Centrexion Therapeutics. The partnership aligns with Centrexion's focus on non-opioid pain relief and immunology medicine development, leveraging Boehringer Ingelheim's resources and expertise in these therapeutic areas.
• National Institutes of Health (NIH)coreStrategic or Co-development PartnerNIH is listed as a partner supporting Centrexion Therapeutics' focus on high-value markets with significant unmet need. The collaboration benefits from governmental support for non-opioid pain drug development initiatives.
• SanoficoreStrategic or Co-development PartnerSanofi is listed as a prestigious partner of Centrexion Therapeutics, collaborating on focus areas of non-opioid pain relief and immunology. The partnership positions Centrexion among leading pharmaceutical companies committed to addressing significant unmet medical needs.

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Boehringer Ingelheim: Boehringer Ingelheim is a named Centrexion partner with a global immunology portfolio (including IL-23 and IL-36 programs). It represents the kind of large-cap incumbent with whom Centrexion's immunology assets would most plausibly be partnered or acquired.
• Eli Lilly and Company: Lilly is a named strategic partner and equity investor in Centrexion, and operates a broad immunology and pain pipeline (including migraine and autoimmune assets) at global scale. It is a likely strategic acquirer and a benchmark for what successful commercial scale-up of Centrexion's assets could look like.
• Sanofi: Sanofi is a named Centrexion partner and one of the largest global immunology companies (Dupixent franchise, multiple autoimmune programs). It is a directly comparable incumbent in the immunology space where Centrexion is building its second therapeutic area.
• Pfizer: Pfizer is the company Kindler formerly led and remains the largest global pain and immunology incumbent. It is a directly relevant incumbent and a leading candidate to partner with or acquire late-stage non-opioid pain assets.

Direct peers

• Trevena: Trevena developed oliceridine (Olinvyk), an IV opioid with a differentiated profile, and has historically pursued non-opioid pain mechanisms. It is a direct clinical-stage peer in non-opioid pain development.
• Cara Therapeutics: Cara is a late-stage biopharma developing difelikefalin (Korsuva) for chronic pruritus and pain in inflammatory conditions. It is a similar-sized, clinical/commercial-stage peer with overlapping pain and immunology positioning.
• Pacira BioSciences: Pacira is a commercial-stage leader in non-opioid pain management (Exparel, iovera°) and the most established pure-play in the non-opioid pain category. It represents the kind of commercial franchise Centrexion's pipeline could ultimately support or compete with.
• Vertex Pharmaceuticals: Vertex's NaV1.8 inhibitor suzetrigine (Journavx) is the leading first-in-class non-opioid pain therapeutic, approved by FDA in early 2025. Vertex is the most direct competitor in non-opioid pain and the benchmark for the commercial opportunity Centrexion is pursuing.
• Kiniksa Pharmaceuticals: Kiniksa is a clinical-to-commercial immunology-focused biotech developing biologics for autoinflammatory and autoimmune diseases. Its late-stage I&I pipeline and similar scale make it a directly comparable peer to Centrexion's immunology franchise.
• Collegium Pharmaceutical: Collegium is a specialty pain-management company with both branded and non-opioid pain products. It is a direct commercial-stage peer competing for the same physician and payer relationships that any Centrexion launch would target.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/CentrexionTX
• LinkedInlinkedin.com/company/centrexion-therapeutics-corp-

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds12 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centrexion Therapeutics